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Background: Studies in chronic noncancer pain settings have found that opioid use increases 
health care utilization. Despite the key role of analgesics, specifically opioids, in the setting of 
cancer pain, there is no literature to our knowledge about the relationship between adherence to 
prescribed around-the-clock (ATC) analgesics and acute health care utilization (hospitalization) 
among patients with cancer pain.
Purpose: To identify adherence patterns over time for cancer patients taking ATC analgesics 
for pain, cluster these patterns into adherence types, combine the types into an adherence risk 
factor for hospitalization, identify other risk factors for hospitalization, and identify risk factors 
for inconsistent analgesic adherence.
Materials and methods: Data from a 3-month prospective observational study of patients 
diagnosed with solid tumors or multiple myeloma, having cancer-related pain, and having at 
least one prescription of oral ATC analgesics were collected. Adherence data were collected 
electronically using the medication event-monitoring system. Analyses were conducted using 
adaptive modeling methods based on heuristic search through alternative models controlled by 
likelihood cross-validation scores.
Results: Six adherence types were identified and combined into the risk factor for hospitaliza-
tion of inconsistent versus consistent adherence over time. Twenty other individually significant 
risk factors for hospitalization were identified, but inconsistent analgesic adherence was the 
strongest of these predictors (ie, generating the largest likelihood cross-validation score). These 
risk factors were adaptively combined into a model for hospitalization based on six pairwise 
interaction risk factors with exceptional discrimination (ie, area under the receiver-operating-
characteristic curve of 0.91). Patients had from zero to five of these risk factors, with an odds 
ratio of 5.44 (95% confidence interval 3.09–9.58) for hospitalization, with a unit increase in 
the number of such risk factors.
Conclusion: Inconsistent adherence to prescribed ATC analgesics, specifically the interaction 
of strong opioids and inconsistent adherence, is a strong risk factor for hospitalization among 
cancer outpatients with pain.
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Introduction
Patients with cancer experience multiple and burdensome care transitions, including 
hospitalizations and greater use of emergency departments.1–8 Improvements in overall 
cancer survival make it imperative to understand factors that relate to unnecessary 
acute health care utilization among patients with cancer.
Analgesics remain the predominant paradigm of cancer pain management, and the 
majority of the patients with moderate-to-severe cancer pain are treated with opioids. 
In the US, the prevalence of insured people with opioid claims has increased, and 
individuals with cancer have significantly more pharmacy claims, as well as claims 
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for higher doses of opioids.9 A recent report by the Medicare 
Payment Advisory Commission showed that 1.1 million 
Medicare Part D (drug coverage) beneficiaries with cancer 
received 6.2 million opioid prescriptions or an annual aver-
age of 5.5 prescriptions per beneficiary, accounting for a cost 
of $0.26 billion.10 A number of studies, conducted mainly 
in chronic noncancer pain (CNCP) settings, have found that 
opioid use increases adverse events and acute health care 
utilization.11–13 Patients who are prescribed opioids incur 
higher health care costs in multiple health care utilization 
domains, including inpatient, outpatient emergency depart-
ment, physician and pharmacy services, and other outpatient 
settings.14 Despite the key role of analgesics in the setting of 
cancer pain, there is no literature to our knowledge about the 
relationship between adherence to prescribed around-the-
clock (ATC) analgesics and health care utilization among 
outpatients with cancer pain.
We are not aware either of any studies that have typified 
patterns of analgesic adherence for cancer pain using objec-
tive adherence measures. Patterns of adherence are expected 
to differ among patients, based on motivational, clinical, and 
circumstantial factors, such as analgesic beliefs and fears,15–21 
self-efficacy and satisfaction with pain management,22 and 
access and cost-related concerns.23 Adherence also varies by 
type of analgesics being prescribed and complexity of the 
medication regimen. In one study of self-reported adherence 
to analgesia for cancer pain, a majority (51%) of patients 
reported lower levels of analgesic adherence.24 Only 9% 
were in the high-analgesic-adherence group.24 It is not clear 
how different patterns of analgesic use for cancer pain may 
relate to health care utilization outcomes.
This study is a secondary analysis of a 3-month prospec-
tive observational study designed to investigate preference 
and adherence to prescribed ATC analgesia in outpatients 
with cancer pain.25,26 A serendipitous finding not addressed in 
the original study was that ATC analgesic adherence patterns 
predicted 3-month hospitalization in outpatients with cancer 
pain. We present the analyses pertaining to this finding here. 
The specific aims were:
1. to assess unique types of analgesic adherence patterns 
using MEMS® (medication event-monitoring system; 
MVW Switzerland Ltd., Sion, Switzerland) over time in 
outpatients with cancer pain who were prescribed ATC 
analgesics
2. to investigate if the unique types of analgesic adherence 
patterns over time predict health care utilization outcomes 
(hospitalizations) in this sample of cancer outpatients who 
were prescribed ATC analgesics
3. to identify predictors of inconsistent analgesic adherence 
patterns over time in this sample of cancer outpatients 
who were prescribed ATC analgesics.
Materials and methods
study design and sample
A prospective observational study with repeated measures at 
two time points, ie, baseline and 3 months, was employed. 
Participants (n=196) were recruited between December 2009 
and August 2011 from two outpatient medical oncology 
clinics of a large academic medical center in Philadelphia. 
Patients were invited to participate in the study if they were 
self-identified as African-American or white, at least 18 years 
of age, diagnosed with solid tumors or multiple myeloma, 
having cancer-related pain, and had at least one prescription 
of oral ATC analgesics. Patients were excluded from partici-
pation if they were prescribed ATC analgesics using only a 
transdermal system (eg, fentanyl patch) due to limitations of 
MEMS bottles. The study was approved by the Institutional 
Review Board of the University of Pennsylvania, and all 
participants provided informed consent.
study measures
Prescribed ATc analgesics
The information regarding prescribed ATC analgesics (index 
analgesic) was collected based on patients’ self-report dur-
ing baseline survey, and was triangulated with patients’ 
electronic medical records. Index analgesics were coded 
according to the World Health Organization (WHO) anal-
gesic ladder.27,28 This includes step 1 (nonopioid analgesics), 
step 2 (weak-opioid analgesics, such as codeine), and step 3 
(strong opioids, such as morphine, oxycodone, and metha-
done). We further coded the strong opioids (WHO step 3) 
as immediate-release versus extended- or sustained-release 
(long-acting) opioids.
MeMs analgesic adherence
Analgesic adherence was captured using MEMS. MEMS 
is a medication bottle with a microprocessor that records 
openings of the MEMS cap in real time. Dose adherence 
was the primary measure for the parent study of ATC 
analgesic adherence, defined as the percentage of the total 
number of prescribed doses that were actually taken by the 
participant.
Each participant was instructed on the correct use of 
the MEMS bottle at baseline, followed by a phone call 
within the first 7 days. Participants were asked about 
their use of MEMS and if they had any questions about 
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its proper use. Participants were instructed to 1) use the 
MEMS bottle only to take the index analgesic, 2) take the 
prescribed analgesic from the MEMS bottle for the entire 
duration of the study, including any refills for the index 
medication, 3) notify any changes in the medication’s 
dose or frequency to the study staff, and 4) document 
any instances of bottle openings other than when taking 
the index medications in a medication logbook provided 
by the study staff.
Drug, dose, and frequency of change of the index 
medication
PowerView (MVW Switzerland Ltd., Sion, Switzerland) 
software was used to record MEMS adherence. If the index 
medication or its frequency changed over the study period, a 
new medication entry (phase) was created, with the previous 
phase ending at PowerView’s default time of 2.59 am on 
the day of the change and the next phase beginning at 3 am. 
In the event of a dose change of the index medication over 
the study period, the average of the two (or more) dosages 
was reported without creating a new phase. If a participant 
recorded in the log having taken doses that the MEMS 
bottle did not record, the events were added to the MEMS 
data before computation. This could occur, for example, if a 
patient took out four pills at once for a 2-day trip. Similarly, 
if a patient reported extra openings for reasons other than 
when taking the index medication, extra openings were 
deleted from the MEMS adherence computation. Excluded 
events included openings to count remaining pills, accidental 
openings, and openings to fill the bottle with refilled index 
medication.
hospitalizations
Data on hospitalization (including the name of the facility, 
dates of admission, and reason for admission) were gathered 
based on self-report between the index period (baseline and 
3 months) and review of study logs and patients’ medical 
records. The duration of hospitalization was calculated by 
subtracting the admission date from the discharge date. 
The hospitalization periods were adjusted in the adherence 
computation as unmonitored periods starting on the calendar 
day of admission at 3 am and ending on the calendar after 
discharge at 2.59 am.
covariates and confounders
Preference for analgesic treatment
Choice-based conjoint analysis, a trade-off analysis 
technique, was used to assess preferences and trade-offs 
patients employ in using prescribed analgesics. The detailed 
methodology we used to design and validate the choice-
based conjoint experiment has been described previously.25 
Trade-offs were elicited on five analgesic attributes: 1) type 
of analgesic, 2) percentage pain relief with analgesics, 3) type 
of side effects, 4) severity of side effects, and 5) out-of-pocket 
cost of analgesics.
Pain severity and pain-related function
The Brief Pain Inventory was used to assess pain sever-
ity (four items: pain at its worst, least, average, and now) 
and pain-related functional interference (seven items: 
general activity, mood, walking ability, normal work, 
relationships, sleep, and enjoyment of life).29 Each item 
is scored on a 0–10 scale (0= no pain and 10= pain as bad 
as you can imagine; 0= no interference and 10= interferes 
completely). The psychometrics of the Brief Pain Inventory 
are well-established, with a Cronbach’s α that ranges from 
0.77 to 0.91.
Pain Management index
The Pain Management Index (PMI) is a measure of adequacy 
of pain treatment based on the WHO guidelines for treating 
cancer pain27,28 and on the most potent analgesic prescribed to 
a patient relative to the level of their reported pain. The PMI 
is calculated by subtracting the patient’s “worst pain” score 
(from the Brief Pain Inventory, coded as mild, moderate, or 
severe) from the most potent analgesia prescribed according 
to the three-step WHO analgesic ladder. A negative PMI 
score indicates inadequate analgesic prescription relative to 
the reported pain level.
Analgesic attitudes and barriers
The Barriers Questionnaire (BQ)-II,20 a widely used measure 
to assess patients’ beliefs about the management of cancer 
pain, was employed. The BQ-II is a 27-item instrument 
that elicits patients’ pain-management concerns in eight 
domains: 1) fear of addiction, 2) fear of tolerance, 3) fear 
of side effects, 4) fatalism about cancer pain, 5) desire to 
be a good patient, 6) fear of distracting health provider 
from treating cancer, 7) fear that the analgesics impair the 
immune system, and 8) concern that analgesics may mask 
ability to monitor illness symptoms. The responses range 
from 0 (do not agree) to 5 (agree very much). The scoring 
is based on sums for items for the total scale and subscales 
(physiological, fatalism, communication, and harmful 
effects). The internal consistency of the scale is excellent, 
at 0.89.20
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Analgesic side effects
Analgesic-related side effects were assessed using the Medi-
cation Side-Effects Checklist. This elicits information on the 
presence and severity of eight common analgesic side effects 
during the past week (0–10, no severity–extreme severity). 
The internal consistency reliability is greater than 0.80.
intentional versus unintentional nonadherence
A validated self-report measure, the Morisky Medication 
Adherence Scale, was used to elicit intentional (active) and 
unintentional (passive) dimensions of analgesic nonadher-
ence. Items corresponding to unintentional nonadherence 
include “I sometimes forget to take my pain medicine” and 
“I am sometimes careless about taking my pain medicine”. 
Items corresponding to intentional nonadherence include 
“When I feel better, I sometimes stop taking my pain 
medicine” and “If I feel worse when I take the pain medicine, 
sometimes I stop taking it”. The participants were instructed 
to indicate the extent to which they agreed with each state-
ment on the Morisky 4-point scale. The scores for the four 
items were aggregated to give a score ranging from 0 to 4; 
higher scores indicated higher levels of reported nonadher-
ence. The tool’s internal consistency in different studies has 
ranged from 0.61 to 0.73.24,30
social support Questionnaire
A six-item questionnaire was used to measure participants’ 
perceptions of social support and satisfaction with social 
support.31 The first part of the questionnaire asks participants 
to list individuals who provide social support in that domain 
(eg, whom they can count on to be dependable when they 
need help), and the second part of the questionnaire asks 
participants to indicate their level of satisfaction with this 
support. This questionnaire is a shortened version of the 
original 27-item Social Support Questionnaire.31
sociodemographic, pain-treatment, and illness 
variables
Self-reported sociodemographic data were gathered on age, 
sex, self-identified race, marital status, education, health insur-
ance, household income, job status, and health literacy. Health 
literacy was assessed using three brief screening questions:32 
“How often do you have someone help you read hospital 
materials?”; “How confident are you filling out medical 
forms by yourself?”; and “How often do you have problems 
learning about your medical condition because of difficulty 
understanding written information?” These questions have 
been found to be effective in detecting inadequate health 
literacy (areas under the receiver-operating-characteristic 
[ROC] curve of 0.87, 0.80, and 0.76, respectively). This 
brief measure has also been found to perform well against the 
widely used Test of Functional Health Literacy in Adults.32 
Responses range from “always” to “never”.
Pain treatment-related variables included total number 
and types of analgesics and coanalgesics, most potent anal-
gesic prescribed, hours pain medications are effective, and 
pain relief with analgesics. Illness-related variables collected 
from patients’ medical records included stage of cancer, time 
since cancer diagnosis, past history of drug or substance 
abuse, comorbidities to compute the Charlson Comorbidity 
Index,33 presence of chronic kidney disease, and presence 
of depression.
statistical analysis
Adaptive modeling
Linear, logistic, and Poisson regression models for continuous, 
discrete, and count/rate outcomes can be adaptively modeled 
in terms of subsets of predictors with a two-phase process 
based on an heuristic search.34 The model is first expanded 
by systematically adding in possibly power-transformed 
predictors, then contracted by removing unneeded terms and 
readjusting the powers for the remaining transforms.34
likelihood cross-validation
Likelihood cross-validation (LCV) scores are used to evalu-
ate and compare alternative regression models for the same 
outcome. The data are randomly partitioned into k disjoint 
subsets called folds. Likelihoods (or likelihood-like func-
tions, eg, extended quasilikelihoods)35 for data in each fold 
are computed with model parameters estimated using the 
data in the other folds. These deleted fold likelihoods are 
combined into an LCV score, which is “larger is better”. 
Tolerance parameters indicating tolerable decreases in the 
LCV scores at given stages of the adaptive modeling process 
are used to control that process.
lcV-ratio tests
A model with a larger LCV score is not necessarily more 
preferable; the difference needs to be substantial. This can 
be determined using χ2-based LCV-ratio tests, analogous to 
likelihood-ratio tests. These are expressed in terms of a cutoff 
for a substantial (distinct, significant) percentage decrease in 
the LCV score for the model with the lower score compared 
to the model with the larger score. If the percentage decrease 
is larger than the cutoff, the model with the larger LCV score 
provides a substantial improvement over the model with the 
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smaller LCV score. Otherwise, the model with the lower score 
is a competitive alternative, and if simpler (eg, based on fewer 
terms or not including interactions), it is then preferable as 
a parsimonious, competitive alternative. The cutoff changes 
with the sample size. An LCV-ratio test is used to control 
the contraction phase of the adaptive modeling process. The 
contraction continues as long as the next contracted model is 
a competitive alternative to the prior model and is also more 
parsimonious since it has one less term.
LCV-ratio tests are more conservative than tests for zero 
coefficients. For example, models based on a single risk fac-
tor can have a significant (P,0.05) slope for that risk factor, 
but the percentage decrease for the constant model compared 
to the model with that risk factor can be less than the cutoff for 
the data. Examples are provided in the “Results” section.
individual patient-adherence patterns
MEMS cap openings were grouped into intervals within 
each individual patient’s study participation period of at least 
3 days. Counts and rates per day per prescribed dose were 
computed for each such interval and modeled using Poisson 
regression methods. Adaptive modeling was used to fit 
possibly nonlinear curves for mean adherence and adherence 
variability (based on dispersions)35 over time in the study. 
LCV scores were computed using extended quasilikelihoods 
based on the Poisson distribution.
Adherence types
Estimates of mean adherence and adherence variability at 
20 proportionally spaced time points within each patient’s 
study participation period (and so a vector with 40 entries) 
were clustered. A variety of hierarchical clustering procedures 
and k-means clustering, each with varying numbers of clus-
ters, were considered in this analysis as long as each cluster 
included at least 5% of the observations (to avoid sparse cases). 
LCV scores were computed using mixtures of multivariate 
normal distributions and then maximized to identify the most 
appropriate clustering alternative and number of clusters.
risk factors for hospitalization
Individual risk factors for being hospitalized during the 
3 months of patients’ study participation were adaptively 
determined using logistic regression models with LCV 
scores based on the Bernoulli distribution. Possible predic-
tors included the adaptively generated adherence types, the 
commonly used dose-adherence measure, and the baseline 
measures described earlier. Each of the 27 items of the BQ-II 
was considered, as well as its total and subscales, to address 
more fully the impact of analgesic attitudes and barriers 
on hospitalization. Values for categorical predictors were 
combined into a two-level risk factor, generating the best 
LCV score. Values for ordinal and continuous predictors 
were combined into two levels corresponding to smaller 
or larger values than each observed value; the observed 
threshold value generating the best LCV score determined 
the associated risk factor. Groupings were considered only 
if both levels corresponded to at least 10% of the observa-
tions (to avoid sparse cases). The level generating an odds 
ratio (OR) .1 was used to define the associated risk factor 
for hospitalization. When a predictor had missing values, 
observations with missing values were combined with the 
non-risk factor-level observations to be conservative and so 
that the risk factor level was based entirely on observations 
with nonmissing predictor values.
Categorizing ordinal or continuous predictors into two 
levels has the potential for substantial loss of predictive 
capability. This issue was addressed by comparing LCV 
scores for the categorized risk factor to the model linear in 
the associated predictor. This comparison is only feasible for 
predictors with no missing values.
Individually significant (P,0.05) risk factors for hos-
pitalization were identified first. Then, these were used 
to adaptively generate a multiple risk-factor model for 
hospitalization. These risk factors were also used to adap-
tively generate a multiple risk-factor plus pairwise-interaction 
model. Pairwise interactions were adaptively generated as 
long as the associated two levels corresponded to at least 10% 
of the observations (to avoid sparse cases) and the estimated 
slope was positive (so that it was a risk factor rather than a 
protective factor). These models were compared using LCV 
scores to identify the most appropriate model for the data. 
For some risk factors, there were no patients who were hos-
pitalized for any of the risk-factor levels, causing problems 
for standard Wald χ2 tests (as commonly used for standard 
logistic regression models) of zero slopes for those risk 
factors, but not for associated robust empirical Wald z-tests 
(as used for generalized linear models). Consequently, for 
models with such risk factors, robust empirical Wald z-tests 
were reported instead.
Collinearity for the most appropriate model was assessed 
using Nagelkerke R2 values for logistic regression models of 
each risk factor or interaction in terms of the other risk factors 
and interactions. The count of how many of this model’s risk 
factors and interactions patients had was used as a risk index. 
The area under the ROC curve was computed for models, 
as well as the cross-validated accuracy (the percentage 
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of observations correctly predicted using the maximum 
likelihood estimate, ie, the outcome value with the greater 
estimated probability using deleted parameter estimates and 
the risk-factor settings for an observation).
risk factors for inconsistent adherence
The two-level risk factor based on the adaptive adherence 
types generated for predicting hospitalization was modeled 
using logistic regression in the same way as hospitalization. 
Possible predictors considered in these analyses were the 
baseline measures described earlier other than those related 
to adherence. Note that the threshold for a risk factor for 
inconsistent adherence based on a given variable can be dif-
ferent than the threshold for the risk factor for hospitalization 
based on that same variable.
Results
Baseline descriptive statistics
Usable MEMS data were available for 191 (97.4%) of the 
study participants. Descriptive statistics for these participants 
are provided in Table 1 for variables in the categories of 
1) sociodemographic; 2) illness; 3) pain, function, and pain 
treatment; 4) analgesic attitudes and barriers; and 5) subjec-
tive adherence.
individual patient-adherence patterns
Figure 1 displays grouped adherence data along with mean 
adherence (the inner curve) and unit error bounds (the lower 
and upper curves representing ±1 estimated standard devia-
tion in adherence rates) for selected patients 1–6. The raw 
data points are displayed as diamonds. These correspond to 
counts of MEMS cap openings in associated subintervals of 
time during study participation normalized by the length in 
days of the subintervals and by the prescribed rate. There-
fore, the ideal mean adherence curve has a constant value 
of 1 at all times, with smaller variability around the value of 
1 representing better adherence.
Patient 1 had consistent mean adherence over length of 
the study, with relatively low adherence variability. Patient 2 
also had consistent mean adherence, but a little lower than 
the ideal value of 1 and with more variability than patient 1. 
Patient 3 had mean adherence at the start of the study close 
to 1 with low adherence variability, but mean adherence 
decreased somewhat over time while adherence variability 
increased. Patient 4 had moderate levels of mean adherence 
for most of the study, with more adherence variability than 
patient 1 but less than patient 2. Patient 5 had low mean 
adherence throughout the study, with low levels of adher-
ence variability. Patient 6 had mean adherence starting out 
Table 1 Baseline variables
Variable type Variable Range n (%) Mean (SD)
sociodemographic Age, years (n=191) 23–75 53.8 (11.2)
education (n=191) elementary 3 (1.6)
high school 62 (32.5)
college/trade school 94 (49.2)
More than college 32 (16.7)
employment status (n=191) employed full-time outside the home 40 (20.9)
employed part-time outside the home 11 (5.8)
employed full-time in the home 4 (2.1)
employed part-time in the home 4 (2.1)
retired 41 (21.5)
Unemployed 24 (12.6)
Other 67 (35.1)
health literacy, (n=191) 3–15 13.1 (2.6)
income, Us$ (n=191) ,10,000 26 (13.6)
10,000–20,000 24 (12.6)
.20,000–30,000 18 (9.4)
.30,000–50,000 31 (16.2)
.50,000–70,000 34 (17.8)
.70,000–90,000 23 (12.0)
.90,000 35 (18.3)
Primary insurance (n=190) Private 99 (52.1)
Medicare 37 (19.5)
Medicaid 24 (12.6)
Multiple 24 (12.6)
VA/other 6 (3.2)
(Continued)
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Table 1 (Continued)
Variable type Variable Range n (%) Mean (SD)
Marital status (n=191) Married 103 (53.9)
separated 14 (7.3)
Divorced 28 (14.7)
Widowed 8 (4.2)
never married 38 (19.9)
race (n=191) Black/African-American 79 (41.4)
White 112 (58.6)
social support, (n=191) 0.17–9.00 3.7 (2.1)
social support satisfaction (n=191) 1–6 (very dissatisfied–very satisfied) 5.6 (0.8)
illness cancer stage (n=191) i 20 (10.5)
ii 28 (14.7)
iii 34 (17.8)
iV 60 (31.4)
Unknown or unsure 49 (25.7)
Time since cancer diagnosis, months (n=191) 1–120 37.4 (35.8)
charlson comorbidity index (n=191) 0–13 4.3 (2.7)
general health (n=191) excellent 9 (4.7)
Very good 23 (12.0)
good 58 (30.4)
Fair 68 (35.6)
Poor 33 (17.3)
Physical health not good, days within last 30 
(n=191)
0–30 14.6 (10.7)
Mental health not good, days within last 30 
(n=191)
0–30 9.6 (10.8)
Past history of substance abuse (n=191) no 157 (82.2)
Yes 34 (17.8)
Presence of chronic kidney disease (n=191) no 103 (53.9)
Yes 88 (46.1)
Presence of depression (n=191) no 110 (57.6)
Yes 81 (42.4)
Pain, function, and 
pain treatment
Duration of cancer pain, months (n=175) 0–120 29.9 (31.0)
Worst pain in last week (n=191) 0–10 (no pain–pain as bad as you can imagine) 6.8 (2.4)
Average pain in last week (n=191) 0–10 (no pain–pain as bad as you can imagine) 4.9 (2.0)
least pain in last week (n=191) 0–10 (no pain–pain as bad as you can imagine) 3.3 (1.9)
Pain-related functional interference score 
(n=191)
0–70 (does not interfere–completely 
interferes)
34.6 (15.8)
Pain relief with medications (n=191) 1–10 (10%–100%) 7.3 (2.0)
hours pain medications effective (n=191) Does not help at all 1 (0.5)
1 6 (3.1)
2 15 (7.9)
3 27 (14.1)
4 48 (25.1)
5 82 (42.9)
.12 12 (6.3)
Pain Management index (n=191) -2 4 (2.1)
-1 12 (6.3)
0 83 (43.5)
1 61 (14.7)
2 28 (14.7)
3 3 (1.6)
Total number of analgesics prescribed 
(n=191)
1 41 (21.5)
2 103 (54.9)
3 36 (18.9)
4 11 (5.8)
(Continued)
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Table 1 (Continued)
Variable type Variable Range n (%) Mean (SD)
Total number of coanalgesics prescribed 
(n=191)
0 149 (78.0)
1 35 (18.3)
2 7 (3.7)
WhO analgesic step, index medication 
(n=191)
step 1 18 (9.4)
step 2 20 (10.5)
step 3 153 (80.1)
Prescription of long-acting opioids (n=191) no 82 (42.9)
Yes 109 (57.1)
how often prescribed medication taken per 
day (n=191)
not every day 2 (1.0)
1–2 times 71 (37.2)
3–4 times 81 (42.4)
5–6 times 29 (15.2)
.6 times 8 (4.2)
number of analgesic side effects, Msec 
(n=191)
0–8 3.9 (2.4)
severity of side effects, Msec (n=191) 8–80 (not severe–extremely severe) 25.5 (15.9)
number of complementary alternative 
modalities used (n=191)
0–8 2.1 (1.7)
Analgesic attitudes 
and barriers
cBc type of analgesic (n=191) #25% 155 (81.2)
.25% and #50% 17 (8.9)
.50% and #75% 19 (9.9)
cBc pain relief with analgesics (n=191) #25% 83 (43.5)
.25% and #50% 67 (35.1)
.50% and #75% 41 (21.5)
cBc type of side effects (n=191) #25% 145 (75.9)
.25% and #50% 43 (22.5)
.50% and #75% 3 (1.6)
cBc severity of side effects (n=191) #25% 132 (69.1)
.25% and #50% 41 (21.5)
.50% and #75% 18 (9.4)
cBc out-of-pocket cost of analgesics 
(n=191)
#25% 180 (94.2)
.25% and #50% 10 (5.2)
.50% and #75% 1 (0.5)
Analgesic barriers, BQ-ii (n=191) 0–96 66.2 (20.2)
BQ-ii physiological effect severity (n=191) 0–51 30.6 (11.1)
BQ-ii fatalism severity (n=191) 0–15 6.2 (3.5)
BQ-ii communication severity (n=191) 0–28 11.3 (5.2)
BQ-ii harmful effects severity (n=191) 0–30 18.1 (7.3)
subjective 
adherence
i sometimes forget to take my pain 
medicine, MMAs (n=191)
no 127 (66.5)
Yes 64 (33.5)
i am sometimes careless about taking my 
pain medicine (n=191)
no 158 (82.7)
Yes 33 (17.3)
When i feel better, i sometimes stop taking 
my pain medicine (n=191)
no 104 (54.5)
Yes 87 (45.5)
if i feel worse when i take the pain medicine, 
sometimes i stop taking it (n=191)
no 165 (86.4)
Yes 26 (13.6)
Abbreviations: BQ, Barriers Questionnaire; cBc, choice-based conjoint analysis; MMAs, Morisky Medication Adherence scale; Msec, Medication side-effects checklist; 
sD, standard deviation; VA, Veterans Administration; WhO, World health Organization.
at approximately 1 and decreasing to 0 by the end of the 
study, while adherence variability started out very high and 
also decreased over time to 0.
Adherence types
Six adherence types were adaptively generated. Mean 
adherence and adherence-variability centroids (ie, averages 
of the entries of the clustered 40 vectors within each cluster) 
are plotted in Figure 2. Table 2 provides a description of 
these six adherence types, including sizes, characterizations 
of mean adherence and adherence-variability centroids, and 
averages of dose adherence for patients in each adherence 
type. Patients 1–6 had adherence patterns within adherence 
types 1–6, respectively.
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Figure 1 Adherence patterns for selected patients, including observed cap opening rates per day per dose, fitted mean adherence curve, and lower and upper unit error-
bound curves.
risk factors for hospitalization
A total of 32 (16.8%) patients with MEMS data were hos-
pitalized at some point during study participation. Table 3 
contains the 21 individually significant risk factors for hos-
pitalization identified through adaptive modeling.
The strongest individually significant risk factor for 
hospitalization was inconsistent (clusters 1–5) versus 
consistent (cluster 1) adherence (Figure 2), as it generated 
the largest LCV score of 0.66672 for predicting hospital-
ization (LCV scores not reported in Table 3). The cutoff 
for a substantial percentage decrease in the LCV score for 
this data set with 191 observations was 1%. The constant 
model for predicting hospitalization had an LCV score of 
0.63391 with a substantial decrease of 4.92% (ie, greater 
than the cutoff of 1%) compared to the model based on 
inconsistent adherence. The constant model generated a 
substantial percentage decrease for nine (43.9%) of the 21 
risk factors provided in Table 3, indicating the conserva-
tive nature of LCV-ratio tests in comparison to standard 
tests for zero slopes.
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Figure 2 Plots of mean adherence and adherence-variability centroids for adherence types.
Table 2 Description of adherence types
Cluster n (%) Adherence types Average dose 
adherenceMean adherence Adherence variability
1 46 (24.0) high low to moderately low 96.1
2 32 (16.7) high to moderately high low to moderate 85.3
3 34 (17.7) high to moderately high Moderate 82.4
4 31 (16.1) Moderate Moderately low 39.1
5 19 (9.9) low low 11.2
6 30 (15.6) Moderately high to low Very high to very low 43.0
Total 191 (100)
Of the 21 risk factors (Table 3), 17 were based on ordinal 
or continuous variables with no missing data. Two of these 
variables (general health; BQ-II item – pain medicine makes 
you say or do embarrassing things) generated better (larger) 
LCV scores than their associated risk factors, but those risk 
factors generated competitive LCV scores (ie, with percent-
age decrease less than 1%). The other variables generated 
worse (smaller) LCV scores, with four of these variables 
(BQ-II item – confusion from pain medicine cannot be con-
trolled; BQ-II item – if doctors have to deal with pain, they 
won’t concentrate on curing the disease; BQ-II item – pain 
medicine can harm your immune system; dose adherence) 
generating LCV scores with substantial percentage decreases 
compared to their associated risk factors. Consequently, 
not only was no predictive capability lost by categorization 
of these 17 variables, categorization provided substantial 
improvements in predictive capability in four cases.
Table 4 describes the multiple risk-factor model for 
hospitalization adaptively generated considering the 21 risk 
factors provided in Table 3. Hospitalization was predicted 
by the combination of the five risk factors: 1) younger age, 
2) lower health literacy, 3) strong-opioid use, 4) higher BQ-II 
rating that pain medicine can harm your immune system, and 
5) inconsistent adherence.
The LCV score was 0.71116, which was a substantial 
improvement over the best individual risk-factor model, with 
a percentage decrease in the LCV score of 6.25%. The area 
under the ROC curve was 0.85, which is considered excellent 
discrimination.36 The cross-validated accuracy was 83.2% (ie, 
with correct deleted prediction of 159 of 191 observed outcome 
values). Inconsistent adherence was the most important of these 
five risk factors in the sense that its removal from the model 
generated the largest percentage decrease in the LCV score.
Table 5 describes the model for hospitalization adap-
tively generated considering the 21 risk factors provided in 
Table 3 and their pairwise interactions. Hospitalization was 
predicted by the combination of the following six interac-
tion risk factors (and no noninteraction risk factors): 1) 
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Table 3 Individually significant risk factors for hospitalization
Variable type Variable Risk factora At-risk 
group, n (%)
P-valueb OR 95% CIb
sociodemographic Age, years #50 vs .50 65 (34.0) 0.040 2.25 1.04–4.85
employment status employed at home part-time, 
unemployed, or other vs employed 
outside home full- or part-time, 
employed at home full-time, or retired
95 (49.7) 0.003 3.72 1.58–8.78
health literacy #12 vs .12 55 (28.8) 0.016 2.63 1.20–5.73
Primary insurance Medicaid, other, VA, none, or multiple 
vs private, Medicare, or missing
137 (71.7) 0.036 2.31 1.06–5.07
social support #4.67 vs .4.67 141 (73.8) 0.026 4.06 1.18–14.0
illness general health Poor vs better 33 (17.3) 0.026 2.69 1.13–6.41
Pain, function, and 
pain treatment
Worst pain (last week) #5 vs .5 50 (26.2) 0.045 2.26 1.02–5.00
WhO analgesic step (index 
medication)
strong opioid vs nonopioids or weak 
opioids
153 (80.1) 0.050 4.39 1.00–19.3
severity of analgesic side effects $15 vs ,15 137 (71.7) 0.038 3.21 1.07–9.65
Analgesic attitudes 
and barriers
BQ-ii item: weakens immune 
system
$3 vs ,3 50 (26.2) 0.001 3.68 1.67–8.10
BQ-ii item: confusion from pain 
medicine cannot be controlled
$3 vs ,3 32 (16.8) 0.019 2.83 1.18–6.77
BQ-ii item: body becomes used 
to effects
$1 vs ,1 145 (75.9) 0.044 3.58 1.04–12.4
BQ-ii item: can harm immune 
system
$3 vs ,3 44 (23.0) 0.012 2.83 1.26–6.33
BQ-ii item: makes you say or do 
embarrassing things
$1 vs ,1 80 (41.9) 0.012 2.75 1.26–6.02
BQ-ii item: if doctors have 
to deal with pain, they won’t 
concentrate on curing the disease
$1 vs ,1 44 (23.0) 0.003 3.34 1.50–7.47
BQ-ii item: can harm immune 
system
$3 vs ,3 41 (21.5) 0.001 3.80 1.69–8.56
BQ-ii item: won’t work as well if 
you need it later
$3 vs ,3 64 (33.5) 0.033 2.31 1.0–5.00
BQ-ii: physiological effect severity $41 vs ,41 40 (20.9) 0.045 2.35 1.02–5.40
BQ-ii: harmful effect severity $20 vs ,20 77 (40.3) 0.018 2.55 1.17–5.53
subjective 
adherence
Analgesic adherence typec inconsistent (clusters 1–5) vs 
consistent (cluster 1)
146 (76.4) ,0.001 4,630 2,839–7,549
Dose adherence #84.2% vs .84.2% 115 (60.2) 0.027 2.74 1.12–6.70
Notes: areference category follows “vs”; bbased on standard Wald χ2 tests, except where otherwise indicated; cP-values based on robust empirical Wald z-tests. Ors and 
cis are very large because no patients without the risk factor were hospitalized.
Abbreviations: BQ, Barriers Questionnaire; CI, confidence interval; OR, odds ratio; VA, Veterans Administration; WHO, World Health Organization.
Table 4 Multiple risk-factor model for hospitalization
Variable type Variable Risk factora At-risk 
group, n (%)
P-valueb OR 95% CIb
sociodemographic Age, years #50 vs .50 65 (34.0) 0.002 4.51 1.74–11.6
health literacy #12 vs .12 55 (28.8) 0.003 4.40 1.67–11.6
illness –
Pain, function, and 
pain treatment
WhO analgesic step 
(index medication)
strong opioid vs nonopioids 
or weak opioids
153 (80.1) 0.009 7.81 1.67–36.6
Analgesic attitudes 
and barriers
BQ-ii item: can harm 
your immune system
$3 vs ,3 44 (23.0) 0.002 4.79 1.79–12.8
Objective analgesic 
adherence
Analgesic adherence 
typec
inconsistent vs consistent 146 (76.4) ,0.001 17,049 9,557–30,414
Notes: areference category follows “vs”; bbased on robust empirical Wald z-tests; cOrs and cis are very large because no patients without the risk factor were 
hospitalized.
Abbreviations: BQ, Barriers Questionnaire; CI, confidence interval; OR, odds ratio; WHO, World Health Organization.
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strong-opioid use and inconsistent adherence; 2) employed 
at home part-time, unemployed, or other employment status 
and higher BQ-II rating that if doctors have to deal with 
pain, they won’t concentrate on curing the disease; 3) lower 
social support and higher BQ-II rating that using pain medi-
cine can harm your immune system; 4) primary insurance 
Medicaid, other, Veterans Affairs, or none and higher BQ-II 
rating that pain medicine makes you say or do embarrassing 
things; 5) younger age and higher severity of analgesic side 
effects; and 6) lower health literacy and higher severity of 
analgesic side effects.
The LCV score was 0.73603, which was a substantial 
improvement over the multiple risk-factors model, with a 
decrease in the LCV score of 3.38%. The area under the ROC 
curve was 0.91, which is considered exceptional discrimi-
nation.36 The cross-validated accuracy was 85.9% (ie, with 
correct deleted prediction of 164 of 191 observed outcome 
values). The interaction of strong-opioid use and inconsistent 
adherence was the most important of these six interaction 
risk factors, with its removal from the model generating the 
largest percentage decrease in the LCV score.
To assess the possibility of collinearity among these 
six interactions, logistic regression models were computed, 
predicting each of these six interactions as a function of the 
other five. The largest Nagelkerke R2 value for these models 
was 10.8%, indicating that collinearity was not a problem 
for the six-interaction model.
Patients had zero to five of these interaction risk factors. 
Of the 34, 68, 53, 24, eight, and four patients with zero to five 
of these interaction risk factors, respectively, the percentage 
hospitalized was 0, 1.5%, 18.9%, 45.8%, 75.0%, and 100%, 
respectively. The hospitalization-risk index model based on 
the count of the number of these interaction risk factors as 
the only predictor of hospitalization had an LCV score of 
0.74740, which provided a substantial improvement over the 
six-interaction model, with a decrease in the LCV score of 
1.52%. The area under the ROC curve model was excellent, 
at 0.89. The cross-validated accuracy was 85.9% (ie, with 
correct deleted prediction of 164 of 191 observed outcome 
values). The estimated OR for hospitalization with a unit 
increase in the number of these risk factors a patient had was 
5.44, with a 95% confidence interval of 3.09–9.58.
risk factors for inconsistent adherence
A total of 146 (76.4%) patients with MEMS data had incon-
sistent adherence during study participation. Table 6 contains 
the eleven individually significant risk factors for inconsistent 
adherence identified through adaptive modeling. Note that 
thresholds for risk factors are adaptively generated, and so 
the thresholds for inconsistent adherence in Table 6 can be 
different from thresholds for hospitalization in Table 3, eg, 
the threshold for the risk factor based on age is 61 years in 
Table 6 and 50 years in Table 3.
The strongest individually significant risk factor for 
predicting inconsistent adherence, generating the largest 
LCV score of 0.59129, was prescription of ATC analgesics 
other than long-acting opioids (LCV scores not reported 
in Table 6). The cutoff for a substantial decrease in the 
Table 5 Multiple pairwise risk-factor interaction model for hospitalization
Interaction term 1 Interaction term 2 At-risk 
group, n (%)
P-valueb OR 95% CIb
Variable Risk factora Variable Risk factora
WhO analgesic step 
(index medication)
strong opioid vs nonopioids 
or weak opioids
Adherence 
adherence type
inconsistent 
vs consistent
111 (58.1) 0.001 16.50 3.17–85.7
employment status employed at home part-
time, unemployed, or other 
vs employed outside home 
full- or part-time, employed 
at home full-time, or retired
BQ-ii item: if 
doctors have to deal 
with pain, they won’t 
concentrate on 
curing the disease
$1 vs ,1 44 (23.0) 0.006 5.06 1.59–16.1
social support #4.67 vs .4.67 BQ-ii item: can harm 
immune system
$3 vs ,3 41 (21.5) 0.010 4.09 1.40–12.0
insurance type Medicaid, other, VA, none, 
or multiple vs private, 
Medicare, or missing
BQ-ii item: makes 
you say or do 
embarrassing things
$1 vs ,1 80 (41.9) 0.003 8.04 2.03–31.9
Age, years #50 vs .50 severity of analgesic 
side effects
$15 vs ,15 50 (26.2) 0.009 4.23 1.43–12.5
health literacy #12 vs .12 severity of analgesic 
side effects
$15 vs ,15 46 (24.1) 0.016 3.84 1.29–11.4
Notes: areference category follows “vs”; bbased on standard Wald χ2 tests.
Abbreviations: BQ, Barriers Questionnaire; CI, confidence interval; OR, odds ratio; VA, Veterans Administration; WHO, World Health Organization.
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Table 6 Individually significant risk factors for inconsistent adherence
Variable type Variable Risk factora At-risk group, n (%) P-valueb OR 95% CIb
sociodemographic Age, years #61 vs .61 139 (72.8) 0.004 2.85 1.41–5.78
education college, trade school, or 
less vs more than college
159 (83.2) 0.045 2.29 1.02–5.16
income, Us$ #$50,000 vs .$50,000 99 (51.8) 0.014 2.39 1.19–4.77
race Black vs white 79 (41.4) 0.004 3.14 1.45–6.80
illness Time since cancer 
diagnosis, months
#66 vs .66 150 (78.5) 0.010 2.67 1.27–5.64
Physical health not good, 
days within last 30
#29 vs 30 152 (79.6) 0.045 2.19 1.02–4.69
Pain, function, and 
pain treatment
Duration of cancer pain, 
months
#31 vs .31 or missing 122 (63.9) 0.018 2.27 1.15–4.49
WhO analgesic step 
(index medication)
nonopioids or weak 
opioids vs strong opioid
38 (19.9) 0.018 4.41 1.29–15.1
Prescription of long-
acting opioids
no vs yes 82 (42.9) 0.002 3.41 1.57–7.39
Analgesic attitudes 
and barriers
BQ-ii item: body 
becomes used to effects
5 vs ,5 40 (20.9) 0.030 3.36 1.12–10.0
BQ-ii item: very addictive 5 vs ,5 48 (25.1) 0.042 2.63 1.03–6.66
Notes: areference category follows “vs”; bbased on standard Wald χ2 tests.
Abbreviations: BQ, Barriers Questionnaire; CI, confidence interval; OR, odds ratio; WHO, World Health Organization.
Table 7 Multiple risk-factor model for inconsistent adherence
Variable type Variable Risk 
factora
At-risk 
group, n (%)
P-valueb OR 95% CIb
sociodemographic Age, years #61 vs .61 139 (72.8) 0.003 3.38 1.54–7.45
illness –
Pain, function, and pain treatment Prescribed long-acting opioids no vs yes 82 (42.9) 0.005 2.83 1.36–5.87
Analgesic attitudes and preferences –
Notes: areference category follows “vs”; bbased on standard Wald χ2 tests.
Abbreviations: BQ, Barriers Questionnaire; CI, confidence interval; OR, odds ratio.
LCV score was also 1%. The constant model for predicting 
inconsistent adherence had an LCV score of 0.57722 with a 
substantial decrease of 2.38% compared to the model based 
on prescription of ATC analgesics other than long-acting 
opioids. The constant model generated a substantial percent-
age decrease for eight (72.7%) of the eleven risk factors 
provided in Table 6, once again indicating the conservative 
nature of LCV-ratio tests in comparison to standard tests for 
zero slopes.
Of the eleven risk factors provided in Table 6, five were 
based on ordinal or continuous variables with no missing 
data. None of these variables generated better LCV scores 
than their associated risk factors. All five of these variables 
generated LCV scores with substantial percentage decreases 
compared to their associated risk factors. Consequently, 
not only was no predictive capability lost by categorization 
of these five variables, categorization provided substantial 
improvements in predictive capability in all five cases.
Table 7 describes the multiple risk-factor model for 
predicting inconsistent adherence adaptively generated 
considering the eleven risk factors provided in Table 6. 
Inconsistent adherence was predicted by the combination of 
the two risk factors–younger age and prescription of ATC 
analgesics–other than long-acting opioids. The LCV score 
was 0.59857, which was a substantial improvement over the 
best individual risk-factor model, with percentage decrease 
in the LCV score of 1.22%. The area under the ROC curve 
was 0.69, just below good discrimination of 0.70.36 The 
cross-validated accuracy was 73.3% (ie, with correct deleted 
prediction of 140 of 191 observed outcome values). Prescrip-
tion of ATC analgesics other than long-acting opioids was 
the more important of these two risk factors, with its removal 
from the model generating the larger percentage decrease in 
the LCV score.
Table 8 describes the model for inconsistent adherence 
adaptively generated considering the eleven risk factors pro-
vided in Table 6 and their pairwise interactions. Inconsistent 
adherence was predicted by the combination of the follow-
ing three interaction risk factors and one noninteraction risk 
factor: 1) shorter duration of cancer pain and higher BQ-II 
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rating that pain medicine is very addictive, 2) lower income 
and fewer days within last 30 days with physical health not 
good, 3) less education and younger age, and 4) prescription 
of nonopioids or weak opioids.
The LCV score was 0.62541, which was a substantial 
improvement over the multiple risk-factor model, with a 
decrease in the LCV score of 4.29%. The area under the ROC 
curve was 0.77, which is considered good discrimination.36 
The cross-validated accuracy was 78.0% (ie, with correct 
deleted prediction of 149 of 191 observed outcome values). 
The interaction of shorter duration of cancer pain and higher 
BQ-II rating that pain medicine is very addictive was the 
most important of these four interaction and noninteraction 
risk factors, with its removal from the model generating the 
largest percentage decrease in the LCV score.
To assess the possibility of collinearity between these 
four risk factors, logistic regression models were computed 
predicting each of them as a function of the other three. The 
largest Nagelkerke R2 value for these models was 7.3%, indi-
cating that collinearity was not a problem for the interaction 
and noninteraction risk-factor model.
Patients had zero to four of these interaction and noninter-
action risk factors. Of the 61, 77, 35, 16, and two patients with 
zero to four of these risk factors, respectively, the percent-
age with inconsistent adherence was 57.4%, 80.5%, 88.6%, 
100%, and 100%, respectively. The inconsistent-adherence 
risk-index model based on the count of the number of these 
risk factors as the only predictor of inconsistent adherence had 
an LCV score of 0.60890, but with a substantial percentage 
decrease over the four-interaction and noninteraction risk-
factor model. The area under the ROC curve model was good, 
at 0.71. The cross-validated accuracy was 76.4% (ie, with 
correct deleted prediction of 146 of 191 observed outcome 
values). The estimated OR for inconsistent adherence with a 
unit increase in the number of these risk factors a patient had 
was 2.87, with 95% confidence interval of 1.75–4.73.
Discussion
While there have been several studies in the CNCP set-
ting documenting an association between chronic opioid 
therapy and health care utilization and other adverse 
outcomes,11,14,37–41 patients with cancer pain have been 
largely exempt from these investigations.40–47 This is the 
first study to our knowledge that has demonstrated an 
association between prescribed analgesic adherence pat-
terns and acute health care utilization among patients with 
cancer pain.
In this study, 17% of patients with cancer were hospital-
ized, which is considerable given the short 3-month duration 
of observation. Our main finding was that inconsistent 
adherence to prescribed ATC analgesics (as measured using 
MEMS) was the most powerful risk factor for hospitalization 
in both individual risk-factor models and multiple risk-factor 
models that adaptively considered other confounders of 
hospitalization, including pain severity and stage of cancer. 
In addition, we identified that younger age, lower health lit-
eracy, being prescribed a strong (WHO step 3) ATC opioid, 
and belief that pain medicine can harm the immune system 
were the other independent predictors of hospitalization in the 
multivariable model. When we considered relevant interac-
tions, a combination of six interactions (Table 5) provided 
substantial improvement in predictive capability compared 
to the multiple risk-factor model. Of note, there was a linear 
relationship between the number of interactions patients had 
and the risk of hospitalization. For instance, patients with no 
interactions were unlikely to be hospitalized, whereas 75%–
100% of patients with four to five interactions, respectively, 
were hospitalized over the study period. The interaction of 
Table 8 Multiple risk-factor and pairwise interaction model for inconsistent adherence
Interaction term 1 Interaction term 2 At-risk 
group, n (%)
P-valueb OR 95% CIb
Variable Risk factora Variable Risk 
factora
Duration of cancer pain #31 vs .31 or missing BQ-ii item: very 
addictive
5 vs ,5 25 (13.1) ,0.001 7,298c 3,829–13,912c
income, Us$ #50,000 vs .50,000 Physical health not good, 
days within last 30
#29 vs 30 85 (44.5) 0.009 2.88 1.31–6.33
education college, trade school, or 
less vs more than college
Age, years #61 vs 
.61
55 (28.8) 0.009 2.66 1.27–5.54
WhO analgesic step 
(index medication)d
nonopioids or weak 
opioids vs strong opioid
– – 38 (19.9) 0.031 4.11 1.13–14.9
Notes: areference category follows “vs”; bbased on robust empirical Wald z-tests; cOr and ci very large because all patients without the risk-factor interaction had 
consistent adherence; da non-interaction risk factor.
Abbreviations: ci, confidence interval; OR, odds ratio; BQ, Barriers Questionnaire; WhO, World health Organization.
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strong-opioid use and inconsistent adherence was the most 
important of the six interactions.
Consistent with studies in CNCP settings,11,14,37–41 our 
study found an association between prescription of strong 
opioids and health care utilization among cancer outpa-
tients. Importantly, the interaction of strong-opioid use and 
inconsistent adherence was the most important risk factor 
for hospitalization. The available research suggests that 
inconsistent adherence may be a prevalent clinical problem in 
patients with cancer pain. In one study of self-reported adher-
ence to long-acting opioids among patients with advanced 
lung cancer, more than one in four (28%) patients reported 
a medication frequency that did not match the frequency of 
their prescribed daily dose.48 Patients who reported inaccu-
rate frequency were also more likely to have lower reported 
adherence to the prescribed opioids.48 The authors concluded 
that comprehending opioid regimens may be a critical clinical 
indicator of adherence to opioids.
It is important to note how our findings are different from 
those of health utilization in CNCP. Most studies in the CNCP 
setting have compared health care utilization outcomes of 
patients on chronic opioid treatment versus those who are 
not receiving opioid treatment.14,37,38 This approach appears 
mainly due to the debate about the appropriateness of opioids 
for CNCP.49 However, based on current guidelines, opioids 
are important for the treatment of moderate-to-severe cancer 
pain,50 and are the only consistently available and reimbursed 
treatment in the absence of strong evidence on complemen-
tary and alternative treatments for cancer pain.51
Patients with cancer pain may need to manage multiple-
medication regimens, including multiple analgesics and 
coanalgesic prescriptions, making it difficult to comprehend 
medication regimens. The commonly used WHO guidelines 
provide no guidance to prescribers on multiple-opioid 
prescribing.52 Consequently, patients with socioeconomic 
disadvantage, eg, those with lower education, income, health 
literacy, and poor health requiring multiple-medication 
management, may be at particular risk of inconsistent adher-
ence. Indeed, in the present study, inconsistent adherence 
to opioids was predicted by lower education and income 
levels. Medication adherence literature has found household 
income of less than $20,000 and higher out-of-pocket cost 
of medications to be associated with adherence behaviors 
that include decreasing the frequency and dose of prescribed 
medications, avoiding refills or extending time between 
refills.53–56
In considering predictors of inconsistent adherence, pre-
scription of an index analgesic other than long-acting opioids 
was the most important risk factor in the multiple risk-factor 
model. Consistently, in one of the few US studies employing 
objective measures to quantify analgesic adherence among 
cancer outpatients, we previously reported an overall dose 
adherence to ATC analgesics using MEMS to be only 65%.23 
However, on subanalysis, the adherence rate was better for 
strong opioids (69%) and specifically better for long-acting 
opioids (74%).23 In another study of patients with advanced 
lung cancer, researchers reported an adherence rate for long-
acting opioids of 85%; however, adherence in this study was 
monitored based on self-reported measures,48 which tend to 
overestimate rates of adherence by 10%–30%.57–62
Of the risk factors of inconsistent adherence in the present 
study, the interaction of shorter duration of cancer pain 
and higher analgesic belief (BQ-II item – pain medicine is 
very addictive) was the most important. The role of opioid-
related attitudes and barriers and consequent intentional 
nonadherence to analgesia for cancer pain have been widely 
established in previous studies to understand and improve 
cancer-pain outcomes.16,20,63 However, a systematic review64 
and meta-analysis65 showed that the available interventions to 
change opioid-related attitudes and barriers do not improve 
adherence to analgesia. Our findings suggest that patients 
relatively earlier in their cancer diagnosis may be more likely 
to benefit from educational interventions to modify opioid-
related attitudes and barriers.
Importantly, understanding/framing of what should be 
considered opioid-related patient beliefs and barriers versus 
actual opioid-related clinical risks in the light of emerging 
literature in the cancer-pain setting should be clarified in 
these educational training programs. A 2014 National Insti-
tutes of Health Pathways to Prevention Conference (Role 
of Opioids in the Treatment of Chronic Pain) underscored 
the “scant” evidence to guide clinicians about the outcomes 
of long-term opioid therapy. Experts also discussed murky 
boundaries between chronic cancer and CNCP.49 Improved 
survival rates for patients with cancer means that patients are 
living longer with multiple painful conditions due to cancer, 
its treatment, or both; there is increasing attention to early 
integration of pain and symptom management in the disease 
process for cancer patients, making it more likely for cancer 
patients to be on long-term opioid therapy.66
strengths and limitations
This is the only study to our knowledge that has identified 
an empirical typology of analgesic adherence for cancer 
pain using objective adherence measures and linked these 
different types to acute health care utilization. Our study 
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was limited in several respects. Hospitalization was not 
the primary outcome in the parent study; the link between 
analgesic-use patterns and hospitalization was an inciden-
tal finding in our study. Since our primary outcome in the 
original study was not hospitalization, we did not collect 
comprehensive data on all potential confounders in explain-
ing hospitalization outcomes. Also, the study period (3-month 
prospective design) did not allow adequate observation 
period for the range of health care-utilization outcomes to 
occur. We also did not quantify emergency department use 
or aberrant opioid-related behaviors. This latter outcome 
is also important, given the emerging literature about the 
aberrant opioid-related behaviors among cancer patients.67 
Furthermore, MEMS recordings do not guarantee ingestion 
of medications, and cap openings other than taking medica-
tions may result in inaccuracies in adherence monitoring 
(even though we accounted for cap openings for reasons 
other than taking prescribed medications, eg, for medica-
tion refills). Also, the route of opioid use has been found 
to be associated with health care utilization. In one study, 
when compared to oral opioids, transdermal opioids reduced 
health care utilization.68 Due to the limitations of MEMS, we 
excluded patients receiving transdermal system only, which 
may have resulted in an underestimation of the levels of 
adherence in this study.
Conclusion and implications
Opioids carry risks to individuals and society that have 
traditionally been ignored in cancer patients.67,69,70 Due to 
the extent that opioids are used in the cancer-pain setting, 
researchers have voiced concern about safe use of opioids 
in patients with cancer pain, including the need for routine 
opioid risk monitoring.66,67,69,70 While our study did not 
quantify aberrant opioid-related risks in cancer patients, we 
found six unique and vastly varied analgesic adherence types 
in this small sample of cancer outpatients. Studies in CNCP 
have shown that patients receiving opioid therapy experi-
ence greater health care utilization in almost all categories of 
use, including inpatient, outpatient emergency department, 
pharmacy, and physician services.11,14,37–41 In spite of this, 
cancer patients are almost invariably excluded from studies 
of chronic opioid-related outcomes.40–47 Nevertheless, consis-
tent with the studies in noncancer settings, our study found 
an association between prescription of strong opioids and 
health care utilization among cancer outpatients. In effect, 
the interaction of strong-opioid use and inconsistent adher-
ence was the most important risk factor for hospitalization in 
this study. This means that patient and clinician education to 
improve patterns of opioid adherence may be an important 
modifiable risk factor for decreasing unnecessary health care 
use. In the light of our preliminary data, there is also an acute 
need for more rigorous studies to clarify the role of patterns 
of opioid adherence in clinical and health service outcomes 
in patients with cancer pain.
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